Want to see SE:BIOEX full AI Analyst Report?

Bioextrax AB (BIOEX) Price & Analysis

0 Followers

BIOEX Stock Chart & Stats

kr3.19

kr0.10(3.70%)

At close: Mar 06 4:00 PM EST

kr3.19

kr0.10(3.70%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.98

Previous CloseN/A

Volume15.49K

Average Volume (3M)82.14K

Market Cap

kr116.62M

Enterprise Valuekr90.32M

Total Cash (Recent Filing)kr3.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.79

Next Earnings

Aug 21, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding47,601,730

10 Day Avg. Volume104,394

30 Day Avg. Volume82,137

Financial Highlights & Ratios

PEG Ratio0.46

Price to Book (P/B)5.23

Price to Sales (P/S)146.53

P/FCF Ratio-4.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.37

Revenue Forecast (FY)kr2.34M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt balance sheet materially lowers refinancing and interest-rate risk, giving management optionality when cash is tight. This structural conservatism extends the company runway and preserves flexibility to raise capital or prioritize organic commercialization without immediate debt servicing pressures.

Industrial Biotech Core TechnologyOperating in industrial bioprocessing and biorefinery gives Bioextrax exposure to durable sustainability-driven demand for bio-based ingredients. Proprietary process know-how to extract bioactives and convert side streams can create defensible technical differentiation and licensing potential over the medium term.

Diversified Commercialization PathsMultiple revenue avenues — product sales, licensing and contract R&D — provide structural resilience. Licensing and process commercialization can scale with limited capital once validated, while R&D services supply nearer-term contracted revenue and industrial partnerships that support long-term commercialization.

Bears Say

Structurally Negative ProfitabilityRepeated negative gross margins indicate the current cost structure and product economics do not support profitable scaling. Until processes achieve reproducible positive gross profit, the business model requires fundamental operational improvements or higher-margin licensing to deliver sustainable earnings.

Persistent Operating Cash BurnConsistent negative operating and free cash flow with accelerating burn raises the likelihood of external funding needs. This undermines long-term independence, risks dilution or covenant constraints, and limits the firm's ability to invest in scale-up, commercial trials, or partner commitments without new capital.

Eroding Equity BufferDeclining shareholders' equity from consecutive losses weakens the balance-sheet cushion that protects creditors and funds growth. Even with no debt, shrinking equity increases vulnerability to financing shocks and reduces the firm's ability to absorb setbacks or self-fund necessary scale-up activities.

Bioextrax AB News

85X0 Earnings this Week: How Will it Perform?

Bioextrax AB (85X0) is scheduled to report 1st quarter earnings on 05/14/2026. Regarding Q1 estimates, Wall Street analysts...

2M ago

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

4M ago

BIOEX FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is kr116.62M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is Aug 21, 2026 which is in 50 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on May 20, 2026. The company reported -kr0.09 earnings per share for the quarter, beating the consensus estimate of -kr0.1 by kr0.01.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is -0.09.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 47,601,730 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of -kr0.09 in its last earnings report, beating expectations of -kr0.1. Following the earnings report the stock price went up 11.2%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in SE:BIOEX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.